Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone610-254-9200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$18.03 million
Profitability
Miscellaneous
Employees106
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable
Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions
What is Strongbridge Biopharma's stock symbol?
Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."
How were Strongbridge Biopharma's earnings last quarter?
Strongbridge Biopharma plc (NASDAQ:SBBP) released its quarterly earnings data on Wednesday, July, 31st. The biotechnology company reported ($0.30) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.31) by $0.01. The biotechnology company had revenue of $6.08 million for the quarter, compared to the consensus estimate of $4.82 million. Strongbridge Biopharma had a return on equity of 49.92% and a net margin of 181.52%. View Strongbridge Biopharma's Earnings History.
When is Strongbridge Biopharma's next earnings date?
What guidance has Strongbridge Biopharma issued on next quarter's earnings?
Strongbridge Biopharma issued an update on its FY 2019 earnings guidance on Wednesday, July, 31st. The company provided EPS guidance of for the period. The company issued revenue guidance of $18-20 million, compared to the consensus revenue estimate of $19.49 million.
What price target have analysts set for SBBP?
4 Wall Street analysts have issued 12-month target prices for Strongbridge Biopharma's shares. Their forecasts range from $11.00 to $15.00. On average, they expect Strongbridge Biopharma's stock price to reach $12.6667 in the next twelve months. This suggests a possible upside of 423.4% from the stock's current price. View Analyst Price Targets for Strongbridge Biopharma.
What is the consensus analysts' recommendation for Strongbridge Biopharma?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Strongbridge Biopharma.
Has Strongbridge Biopharma been receiving favorable news coverage?
Press coverage about SBBP stock has trended positive on Saturday, InfoTrie reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Strongbridge Biopharma earned a coverage optimism score of 2.5 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the next few days. View News Stories for Strongbridge Biopharma.
Who are some of Strongbridge Biopharma's key competitors?
Some companies that are related to Strongbridge Biopharma include Viking Therapeutics (VKTX), Dermira (DERM), Revance Therapeutics (RVNC), Intra-Cellular Therapies (ITCI), Karuna Therapeutics (KRTX), Syros Pharmaceuticals (SYRS), Milestone Pharmaceuticals (MIST), Aptorum Group (APM), Sinovac Biotech (SVA), Advanz Pharma (CXRXF), Urogen Pharma (URGN), Crinetics Pharmaceuticals (CRNX), Organogenesis (ORGO), CytomX Therapeutics (CTMX) and BioSpecifics Technologies (BSTC).
What other stocks do shareholders of Strongbridge Biopharma own?
Who are Strongbridge Biopharma's key executives?
Strongbridge Biopharma's management team includes the folowing people:
- Mr. Matthew Pauls, CEO, Pres & Director (Age 48)
- Mr. A. Brian Davis, Chief Financial Officer (Age 52)
- Dr. Fredric Cohen, Chief Medical Officer (Age 54)
- Dr. Per Marin M.D., Ph.D., Founder and Sr. Clinical Advisor
- Mr. Peter J. Valentinsson, Sr. VP of Global Technical Operations
Who are Strongbridge Biopharma's major shareholders?
Strongbridge Biopharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.22%), D. E. Shaw & Co. Inc. (1.75%), Essex Investment Management Co. LLC (0.85%), Renaissance Technologies LLC (0.31%), Stonepine Capital Management LLC (0.30%) and Bank of New York Mellon Corp (0.19%). View Institutional Ownership Trends for Strongbridge Biopharma.
Which institutional investors are selling Strongbridge Biopharma stock?
Which institutional investors are buying Strongbridge Biopharma stock?
SBBP stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., D. E. Shaw & Co. Inc., Renaissance Technologies LLC, Bank of New York Mellon Corp, Susquehanna International Group LLP, Vanguard Group Inc., Jane Street Group LLC and Charles Schwab Investment Management Inc.. View Insider Buying and Selling for Strongbridge Biopharma.
How do I buy shares of Strongbridge Biopharma?
Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Strongbridge Biopharma's stock price today?
One share of SBBP stock can currently be purchased for approximately $2.42.
How big of a company is Strongbridge Biopharma?
Strongbridge Biopharma has a market capitalization of $131.14 million and generates $18.03 million in revenue each year. The biotechnology company earns $31.85 million in net income (profit) each year or $0.31 on an earnings per share basis. Strongbridge Biopharma employs 106 workers across the globe.View Additional Information About Strongbridge Biopharma.
What is Strongbridge Biopharma's official website?
How can I contact Strongbridge Biopharma?
Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]
MarketBeat Community Rating for Strongbridge Biopharma (NASDAQ SBBP)
MarketBeat's community ratings are surveys of what our community members think about Strongbridge Biopharma and other stocks. Vote "Outperform" if you believe SBBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
